This application-based continuing pharmacy education activity will provide a “journal club format” discussion for pharmacists and student pharmacists ondelafloxacin, a fluoroquinolone recently approved by the FDA approved for skinand soft tissue infections. Join us to discuss the key trial leading to its approval as well as highlight clinical pearls to clarify its place in therapy for patients in your practice.
At CEimpact, we believe pharmacy teams enhance the health and wellness of patients and communities. We create continuing education that develops and inspires pharmacists and technicians throughout their careers.
This post is related to:
Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.
